Estrella Immunopharma (ESLA) vs Scilex (SCLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Estrella Immunopharma (ESLA) has outperformed Scilex (SCLX) over the past year, losing 67.9% versus a loss of 73.0%. Over five years, ESLA leads with a -95.8% price change compared with -98.6% for SCLX. Scilex is the larger company by market cap ($20.8 million vs $18.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ESLA | SCLX |
|---|---|---|
| Share price | $0.4175 | $2.96 |
| Market cap | $18.16M | $20.82M |
| 1-day change | -0.43% | -15.19% |
| YTD return | -73.24% | -61.03% |
| 1-year return | -67.88% | -72.96% |
| 5-year return | -95.77% | -98.65% |
| Forward P/E | — | 4.05 |
| EPS (TTM) | $-0.25 | $-49.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.15 | $16.81 |
| 52-week low | $0.3611 | $2.62 |
| Distance from 52-week high | -86.75% | -82.39% |
| Analyst consensus | none | — |
| Avg. price target upside | +2774.25% | — |
| Average volume | 38.27K | 53.62K |
| Shares outstanding | 43.50M | 7.03M |
| Employees | — | 34 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Estrella Immunopharma
ESLA stock →Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.
Healthcare · Biotechnology
About Scilex
SCLX stock →Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Healthcare · Drug Manufacturers - General · 34 employees
ESLA vs SCLX FAQ
Which is bigger, Estrella Immunopharma or Scilex?
Scilex (SCLX) is larger, with a market capitalization of $20.82M compared with $18.16M for Estrella Immunopharma (ESLA).
Which stock has performed better over the past year, ESLA or SCLX?
ESLA returned -67.88% over the past 12 months, compared with -72.96% for SCLX (price return, excluding dividends). Past performance does not predict future results.
Are Estrella Immunopharma and Scilex in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Estrella Immunopharma and Drug Manufacturers - General for Scilex.